Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Molecular Partners AG ADR (MOLN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/02/2025: MOLN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $11.04
1 Year Target Price $11.04
| 3 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 28.94% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/02/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 138.81M USD | Price to earnings Ratio - | 1Y Target Price 11.04 |
Price to earnings Ratio - | 1Y Target Price 11.04 | ||
Volume (30-day avg) 4 | Beta 0.52 | 52 Weeks Range 3.36 - 12.22 | Updated Date 07/2/2025 |
52 Weeks Range 3.36 - 12.22 | Updated Date 07/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.13 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1231.73% |
Management Effectiveness
Return on Assets (TTM) -21.44% | Return on Equity (TTM) -33.98% |
Valuation
Trailing PE - | Forward PE 1.78 | Enterprise Value -23413629 | Price to Sales(TTM) 27.93 |
Enterprise Value -23413629 | Price to Sales(TTM) 27.93 | ||
Enterprise Value to Revenue 3.81 | Enterprise Value to EBITDA 1.23 | Shares Outstanding 36874600 | Shares Floating 14882000 |
Shares Outstanding 36874600 | Shares Floating 14882000 | ||
Percent Insiders - | Percent Institutions 9.72 |
Upturn AI SWOT
Molecular Partners AG ADR
Company Overview
History and Background
Molecular Partners AG was founded in 2004 and is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of a class of targeted protein therapeutics known as DARPins. Its initial focus was on ophthalmology and oncology but has expanded since.
Core Business Areas
- DARPin Therapeutics Development: The core business revolves around developing DARPin therapeutics, a novel class of targeted protein therapeutics designed to address limitations of conventional antibody therapies.
- Research and Development: Focuses on the discovery and preclinical development of new DARPin candidates across different therapeutic areas.
- Partnerships and Licensing: Strategic collaborations with pharmaceutical companies to co-develop or license DARPin candidates.
Leadership and Structure
The leadership team consists of experienced executives in biotechnology and pharmaceutical development. The organizational structure comprises research, development, clinical, and commercial teams.
Top Products and Market Share
Key Offerings
- Ensovibep: A DARPin therapeutic developed in collaboration with Novartis for the treatment of COVID-19. Market share is difficult to pinpoint since it is related to COVID-19 vaccines and other treatments which will fluctuate over time. Competitors in this segment include Pfizer (PAXLOVID), Merck (Molnupiravir), and various vaccine manufacturers (MRNA, PFE, NVAX).
- MP0310 (AMG 506): An anti-FAP DARPin immuno-oncology agent being co-developed with Amgen. Specific market share data is currently unavailable, as it is still in development. Competitors are other immuno-oncology drugs such as Keytruda (MRK) and Opdivo (BMY).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, stringent regulatory requirements, and intense competition. Advancements in protein engineering and targeted therapies are driving innovation.
Positioning
Molecular Partners AG is positioned as a leader in DARPin therapeutics, offering potential advantages over traditional antibodies in terms of size, stability, and multi-specificity. Their competitive advantage lies in their DARPin technology platform.
Total Addressable Market (TAM)
The TAM for targeted protein therapeutics is substantial, estimated to be in the billions of dollars, encompassing areas like oncology, ophthalmology, and infectious diseases. Molecular Partners AG is positioning itself to capture a share of this market through its DARPin platform and partnerships.
Upturn SWOT Analysis
Strengths
- Novel DARPin technology platform
- Strategic partnerships with established pharmaceutical companies
- Experienced leadership team
- Potential for rapid drug development
Weaknesses
- Reliance on partnerships for funding and development
- Limited commercial infrastructure
- Clinical trial risks and regulatory hurdles
- Relatively small company size
Opportunities
- Expansion into new therapeutic areas
- Advancement of DARPin candidates through clinical trials
- Increased adoption of targeted protein therapeutics
- Further strategic partnerships
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory setbacks
- Patent disputes
Competitors and Market Share
Key Competitors
- MRK
- BMY
- LLY
- PFE
Competitive Landscape
Molecular Partners AG faces competition from established pharmaceutical companies with greater resources and broader product portfolios. Its competitive advantage lies in its novel DARPin technology, but it needs to navigate regulatory hurdles and secure further partnerships to compete effectively.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been dependent on research milestones, clinical trial progress, and partnership deals.
Future Projections: Future growth is tied to the successful development and commercialization of DARPin therapeutics, expansion of strategic partnerships, and market acceptance of the DARPin technology platform. Analyst estimates can vary widely.
Recent Initiatives: Recent initiatives include advancing clinical trials for lead candidates, expanding research collaborations, and exploring new therapeutic applications for DARPins.
Summary
Molecular Partners AG is a clinical-stage biopharmaceutical company with a novel DARPin technology platform. Its success hinges on the progression of its clinical trials and continued collaboration with larger pharmaceutical companies. The company faces risks associated with drug development and competition, but its innovative technology provides a strong foundation for potential growth. Financial information is not available in real-time, so please refer to official company reports.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Financial News Sources
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share estimates are approximations and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Molecular Partners AG ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-06-16 | Co-Founder, CEO, Member of Management Board & Director Dr. Patrick Amstutz Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 158 | |
Full time employees 158 | |||
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in preclinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and Radio-DARPin Therapy to treat ovarian disease. In addition, the company develops MP0621, a molecular partners' first Switch-DARPin program, which is in preclinical trial designed to induce killing of hematopoietic stem cells (HSCs) as a next-generation conditioning regimen for HSC transplantation (HSCT); and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.